Roumen V Milev1, Peter Giacobbe2, Sidney H Kennedy2, Daniel M Blumberger2, Zafiris J Daskalakis2, Jonathan Downar2, Mandana Modirrousta3, Simon Patry4, Fidel Vila-Rodriguez5, Raymond W Lam5, Glenda M MacQueen6, Sagar V Parikh7, Arun V Ravindran2. 1. Department of Psychiatry, Queen's University, Kingston, Ontario roumen.milev@queensu.ca. 2. Department of Psychiatry, University of Toronto, Toronto, Ontario. 3. Department of Psychiatry, University of Manitoba, Winnipeg, Manitoba. 4. Department of Psychiatry, L'Université Laval, Québec City, Québec. 5. Department of Psychiatry, University of British Columbia, Vancouver, British Columbia. 6. Department of Psychiatry, University of Calgary, Calgary, Alberta. 7. Department of Psychiatry, University of Toronto, Toronto, Ontario Department of Psychiatry, University of Michigan, Ann Arbor, Michigan.
Abstract
BACKGROUND: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. METHODS: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Neurostimulation Treatments" is the fourth of six sections of the 2016 guidelines. RESULTS: Evidence-informed responses were developed for 31 questions for 6 neurostimulation modalities: 1) transcranial direct current stimulation (tDCS), 2) repetitive transcranial magnetic stimulation (rTMS), 3) electroconvulsive therapy (ECT), 4) magnetic seizure therapy (MST), 5) vagus nerve stimulation (VNS), and 6) deep brain stimulation (DBS). Most of the neurostimulation treatments have been investigated in patients with varying degrees of treatment resistance. CONCLUSIONS: There is increasing evidence for efficacy, tolerability, and safety of neurostimulation treatments. rTMS is now a first-line recommendation for patients with MDD who have failed at least 1 antidepressant. ECT remains a second-line treatment for patients with treatment-resistant depression, although in some situations, it may be considered first line. Third-line recommendations include tDCS and VNS. MST and DBS are still considered investigational treatments.
BACKGROUND: The Canadian Network for Mood and Anxiety Treatments (CANMAT) conducted a revision of the 2009 guidelines by updating the evidence and recommendations. The scope of the 2016 guidelines remains the management of major depressive disorder (MDD) in adults, with a target audience of psychiatrists and other mental health professionals. METHODS: Using the question-answer format, we conducted a systematic literature search focusing on systematic reviews and meta-analyses. Evidence was graded using CANMAT-defined criteria for level of evidence. Recommendations for lines of treatment were based on the quality of evidence and clinical expert consensus. "Neurostimulation Treatments" is the fourth of six sections of the 2016 guidelines. RESULTS: Evidence-informed responses were developed for 31 questions for 6 neurostimulation modalities: 1) transcranial direct current stimulation (tDCS), 2) repetitive transcranial magnetic stimulation (rTMS), 3) electroconvulsive therapy (ECT), 4) magnetic seizure therapy (MST), 5) vagus nerve stimulation (VNS), and 6) deep brain stimulation (DBS). Most of the neurostimulation treatments have been investigated in patients with varying degrees of treatment resistance. CONCLUSIONS: There is increasing evidence for efficacy, tolerability, and safety of neurostimulation treatments. rTMS is now a first-line recommendation for patients with MDD who have failed at least 1 antidepressant. ECT remains a second-line treatment for patients with treatment-resistant depression, although in some situations, it may be considered first line. Third-line recommendations include tDCS and VNS. MST and DBS are still considered investigational treatments.
Authors: Esmée Verwijk; Hannie C Comijs; Rob M Kok; Harm-Pieter Spaans; Max L Stek; Erik J A Scherder Journal: J Affect Disord Date: 2012-05-15 Impact factor: 4.839
Authors: Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; Serge Beaulieu; Martin Alda; Claire O'Donovan; Glenda Macqueen; Roger S McIntyre; Verinder Sharma; Arun Ravindran; L Trevor Young; Roumen Milev; David J Bond; Benicio N Frey; Benjamin I Goldstein; Beny Lafer; Boris Birmaher; Kyooseob Ha; Willem A Nolen; Michael Berk Journal: Bipolar Disord Date: 2012-12-12 Impact factor: 6.744
Authors: William M McDonald; Valerie Durkalski; Edward R Ball; Paul E Holtzheimer; Martina Pavlicova; Sarah H Lisanby; David Avery; Berry S Anderson; Ziad Nahas; Paul Zarkowski; Harold A Sackeim; Mark S George Journal: Depress Anxiety Date: 2011-09-02 Impact factor: 6.505
Authors: William K Silverstein; Yoshihiro Noda; Mera S Barr; Fidel Vila-Rodriguez; Tarek K Rajji; Paul B Fitzgerald; Jonathan Downar; Benoit H Mulsant; Simone Vigod; Zafiris J Daskalakis; Daniel M Blumberger Journal: Depress Anxiety Date: 2015-09-18 Impact factor: 6.505
Authors: T E Schlaepfer; C Frick; A Zobel; W Maier; I Heuser; M Bajbouj; V O'Keane; C Corcoran; R Adolfsson; M Trimble; H Rau; H-J Hoff; F Padberg; F Müller-Siecheneder; K Audenaert; D Van den Abbeele; K Matthews; D Christmas; Z Stanga; M Hasdemir Journal: Psychol Med Date: 2008-01-04 Impact factor: 7.723
Authors: Jeffrey J Borckardt; Ziad H Nahas; John Teal; Sarah H Lisanby; William M McDonald; David Avery; Valerie Durkalski; Martina Pavlicova; James M Long; Harold A Sackeim; Mark S George Journal: Brain Stimul Date: 2013-05-21 Impact factor: 8.955
Authors: Diego F Tavares; Martin L Myczkowski; Rodrigo L Alberto; Leandro Valiengo; Rosa M Rios; Pedro Gordon; Bernardo de Sampaio-Junior; Izio Klein; Carlos G Mansur; Marco Antonio Marcolin; Beny Lafer; Ricardo A Moreno; Wagner Gattaz; Zafiris J Daskalakis; André R Brunoni Journal: Neuropsychopharmacology Date: 2017-02-01 Impact factor: 7.853
Authors: Stephanie H Ameis; Zafiris J Daskalakis; Daniel M Blumberger; Pushpal Desarkar; Irene Drmic; Donald J Mabbott; Meng-Chuan Lai; Paul E Croarkin; Peter Szatmari Journal: J Child Adolesc Psychopharmacol Date: 2017-03-27 Impact factor: 2.576
Authors: Sidney H Kennedy; Raymond W Lam; Roger S McIntyre; S Valérie Tourjman; Venkat Bhat; Pierre Blier; Mehrul Hasnain; Fabrice Jollant; Anthony J Levitt; Glenda M MacQueen; Shane J McInerney; Diane McIntosh; Roumen V Milev; Daniel J Müller; Sagar V Parikh; Norma L Pearson; Arun V Ravindran; Rudolf Uher Journal: Can J Psychiatry Date: 2016-08-02 Impact factor: 4.356